The high societal and individual cost of schizophrenia necessitates finding better, more
effective treatment, diagnosis, and prevention strategies. One of the obstacles in this …

The search for immune biomarkers in psychiatric disorders has primarily focused on pro-
inflammatory cytokines. Other immune proteins including chemokines have been relatively …

Context Evidence for symptomatic convergence of schizophrenia and N-methyl-D-aspartate
glutamate receptor (NMDA-R) encephalitis highlights the need for an assessment of …

We have used a translational convergent functional genomics (CFG) approach to identify
and prioritize genes involved in schizophrenia, by gene-level integration of genome-wide …

Current diagnosis of schizophrenia relies exclusively on the potentially subjective
interpretation of clinical symptoms and social functioning as more objective biological …

Introduction: A barrier to preventative treatments for psychosis is the absence of accurate
identification of persons at highest risk. A blood test that could substantially increase …

Aim Over the past several decades, there has been a growing research interest in the role of
inflammation in the pathogenesis of schizophrenia. This review aims to summarize evidence …

Schizophrenia and bipolar disorder share a number of common features, both
symptomatically and biologically. Abnormalities in the neuroimmune and the stress …

Innate immunity has been linked to initiation of Alzheimer's disease and multiple sclerosis.
Moreover, risk of first-episode psychosis (FEP) and schizophrenia (Sz) is increased after …

Identifying biomarkers that can be used as diagnostics or predictors of treatment response
(theranostics) in people with schizophrenia (Sz) will be an important step towards being able …